Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?

insidermonkey.com · 2026-09-05

Testing for Alzheimer’s-related brain changes has traditionally depended on procedures that can be expensive, invasive, or difficult to access.

TickrTrends take: Eli Lilly and Roche's collaborative work on blood-based Alzheimer's diagnostics represents a potential expansion of the company's addressable market in neurodegenerative disease, which could support long-term revenue growth in the Healthcare sector. Given TickrTrends' current undervalued assessment of LLY, developments that improve diagnostic accessibility and patient identification may enhance the commercial potential of the company's pipeline therapies targeting Alzheimer's disease. Investors monitoring the stock's valuation should track how this diagnostic advancement translates into clinical adoption and revenue contribution over time.

Read the full story at insidermonkey.com →